$100M Share Offering Priced by MeiraGTx, Extending Cash Runway to 2028
summarizeSummary
MeiraGTx announced the pricing of an underwritten offering of 11,111,111 ordinary shares at $9.00 per share, expecting to raise approximately $100 million in gross proceeds. This significant capital raise, representing over 10% of the company's market capitalization, follows closely on the heels of positive three-year clinical data for its AAV-hAQP1 gene therapy and the reacquisition of full rights to bota-vec, both announced earlier today. While the offering is dilutive for existing shareholders, the company states the net proceeds, combined with existing cash, will fund operations and capital expenditures, including potential commercial launches, into the second half of 2028. This substantially extends MeiraGTx's cash runway, a critical factor for a clinical-stage biotechnology company. Traders will be watching the market's reaction to the dilution versus the strategic benefit of extended financial stability.
At the time of this announcement, MGTX was trading at $9.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $916.3M. The 52-week trading range was $4.55 to $11.85. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.